Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation
Authors:
Open Access
- 28 June 2021
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (9) , 2375-2380
Abstract
Damage to gut mucosa following conditioning regimens may favour bacterial infections that can trigger graft versus host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Rifaximin, an oral and non-absorbable antibiotic, has been recently proposed as effective prophylaxis to reduce bacterial infections in the gut and consequently acute GvHD in this setting. The present study evaluated safety and outcomes of HSCT patients that were treated with rifaximin prophylaxis at Perugia University Hospital. Rifaximin prophylaxis was introduced as standard of care in HSCT patients in May 2018. We retrieved data from 118 consecutive transplants, and we compared the outcomes of rifaximin-treated patients with historical controls that did not receive antibiotic prophylaxis. While incidences of neutropenic fever, documented bacterial infections, and aGvHD were similar in the two groups, we found an increased frequency of invasive candidiasis and clinically relevant Candida spp. infections in rifaximin-treated patients (5 patients vs 1 patient, 25% [± 0.99%] vs 1% [± 0.01%], p < .0001). Three rifaximin-treated patients experienced life-threating candidemia (2 C. krusei, 1 C. orthopsilosis). Rifaximin was the only factor that increased the risk of Candida spp. infections. Rifaximin could have contributed to microbiome disruption which favoured an outbreak of life-threatening Candida infections. This important complication forced us to halt its use. Larger, prospective studies are needed to assess the impact of rifaximin prophylaxis on incidence of bacterial infections, aGvHD, and survival of HSCT patients.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (20456)
- Università degli Studi di Perugia
This publication has 13 references indexed in Scilit:
- Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms—Where Are We Today?Current Hematologic Malignancy Reports, 2018
- Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation GroupClinical Infectious Diseases, 2017
- The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host diseaseBlood, 2017
- Role of gut flora after bone marrow transplantationNature Microbiology, 2016
- Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantationBone Marrow Transplantation, 2016
- Echinocandin Resistance in CandidaClinical Infectious Diseases, 2015
- Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin TherapyAntimicrobial Agents and Chemotherapy, 2015
- Positions and Numbers of FKS Mutations in Candida albicans Selectively Influence In Vitro and In Vivo Susceptibilities to Echinocandin TreatmentAntimicrobial Agents and Chemotherapy, 2014
- Acquired echinocandin resistance in a Candida krusei blood isolate confirmed by mutations in the fks1 gene.2014
- Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008